Deciphera Pharmaceuticals (NASDAQ:DCPH) Given Market Perform Rating at JMP Securities

JMP Securities restated their market perform rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report published on Tuesday, Benzinga reports.

Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. raised their price target on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a neutral rating in a research note on Wednesday, March 20th. Jefferies Financial Group restated a hold rating and issued a $25.60 price objective (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. Jonestrading restated a hold rating and issued a $25.60 target price on shares of Deciphera Pharmaceuticals in a research note on Monday, April 29th. Barclays raised shares of Deciphera Pharmaceuticals from an underweight rating to an equal weight rating and increased their price target for the stock from $9.00 to $26.00 in a report on Tuesday. Finally, Stifel Nicolaus raised their price objective on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a buy rating in a report on Wednesday, February 7th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Hold and an average price target of $24.17.

Deciphera Pharmaceuticals Price Performance

Shares of NASDAQ DCPH opened at $25.38 on Tuesday. The stock has a market capitalization of $2.09 billion, a P/E ratio of -11.08 and a beta of 0.20. Deciphera Pharmaceuticals has a 1 year low of $9.90 and a 1 year high of $25.47. The company has a 50-day moving average price of $16.56 and a 200-day moving average price of $14.80.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The company had revenue of $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. During the same quarter in the prior year, the company posted ($0.60) earnings per share. The firm’s revenue for the quarter was up 32.9% on a year-over-year basis. As a group, equities research analysts anticipate that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of hedge funds have recently modified their holdings of DCPH. Quest Partners LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. boosted its stake in Deciphera Pharmaceuticals by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares in the last quarter. AJOVista LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter worth approximately $76,000. Exchange Traded Concepts LLC grew its stake in shares of Deciphera Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock worth $169,000 after acquiring an additional 2,649 shares during the last quarter. Finally, Diversified Trust Co bought a new stake in Deciphera Pharmaceuticals during the 4th quarter valued at about $193,000. Hedge funds and other institutional investors own 70.96% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.